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Overcoming cellular senescence is strictly required for virus-driven tumors, including those associated with Epstein-
Barr virus (EBV). This critical step is successfully accomplished by EBV through TERT expression and telomerase
activation in infected cells. We herein review the complex interplay between EBV and TERT/telomerase in EBV-
driven tumorigenesis. Evidence accumulated so far clearly indicates that elucidation of this issue may offer promising
opportunities for the design of innovative treatment modalities for EBV-associated malignancies. Indeed, several
therapeutic strategies for telomerase inhibition have been developed and are being investigated in clinical trials. In this
respect, our recent finding that TERT inhibition sensitizes EBV+ lymphoma cells to antivirals through activation of EBV
lytic replication is particularly promising and provides a rationale for the activation of clinical studies aimed at assessing
the effects of combination therapies with TERT inhibitors and antivirals for the treatment of EBV-associated malignancies.
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More than 90% of the world’s population is infected by
Epstein-Barr virus (EBV), a ubiquitous gammaherpes-
virus that may silently persist in memory B lymphocytes.
Primary infection is usually asymptomatic and when it is
delayed until adolescence or adulthood a benign lym-
phoproliferative disease, known as infectious mono-
nucleosis, may occur. B lymphocytes are the main target
of EBV infection in vivo, although epithelial cells, and T
or Natural Killer (NK) cells may also carry the virus. In-
fection of B lymphocytes is usually non-productive or
latent, whereas intermittent reactivation and virus repli-
cation at epithelial surfaces allow the spreading of EBV
to new hosts. Despite its widespread diffusion and ap-
parent harmlessness, EBV is causally linked to the devel-
opment of both lymphoid and epithelial malignancies,
including Burkitt lymphoma (BL), Hodgkin lymphoma,
post-transplant lymphoproliferations, AIDS-associated
lymphomas, nasopharyngeal and gastric carcinoma [1].
EBV infection of primary B lymphocytes results in per-
manent growth of these cells, an effect promoted by the
full spectrum of EBV-encoded latency proteins, including* Correspondence: rdolcetti@cro.it
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unless otherwise stated.six EBV nuclear antigens (EBNAs) and three latent mem-
brane proteins (LMP-1, LMP-2A, LMP-2B), the so called
latency III program, which can be found in EBV-
transformed lymphoblastoid cell lines (LCLs), in post-
transplant lymphoproliferations and in AIDS-associated
immunoblastic lymphomas [1,2]. A second latency pro-
gram (type II) can be detected in tumor cells of Hodgkin
lymphoma and in nasopharyngeal carcinoma, which ex-
press only EBNA-1 and the LMPs, whereas the most re-
stricted form of EBV latency is characteristic of BL
lymphoma in which only EBNA-1 is expressed. In all
forms of latency, EBV expresses the EBERs, small non-
polyadenylated, non-coding double-strand RNAs, which
may also contribute to EBV-driven B-cell immortalization
[3]. EBV may activate the lytic replication program upon
terminal differentiation of EBV-infected memory B lym-
phocytes into antibody-secreting plasma cells. Although
well equipped to promote the growth of B lymphocytes,
EBV may drive the proliferation of these cells only transi-
ently in immunocompetent hosts. This is due to the exist-
ence of a complex, strictly regulated immunological
control involving various humoral and cellular effectors of
immunity. Through the long time evolutionary adaptation
in humans, the virus has evolved several potent mecha-
nisms by which the type III cells that express the growth
program evade the immune response. This may alsol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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individuals develop EBV-associated lymphomas, even in
the setting of immune deficiency.
Studies carried out with recombinant EBV strains lack-
ing individual latent genes allowed the identification of
the genes that are essential for B-cell immortalization
in vitro. Available evidence indicates that EBNA-2 and
LMP-1 are absolutely required for EBV-mediated B-cell
transformation, whereas a crucial role is played by EBNA-
1, EBNA-3, -5, and -6 [1]. Full immortalization is achieved
through the concerted action of several EBV proteins that
derange cellular pathways controlling growth and/or sur-
vival. These viral proteins usually act cooperatively and
may induce different biologic effects in different cellular
backgrounds. LMP-1 is considered the major EBV onco-
protein, acting as an oncogene in rodent fibroblast cells
[4,5]. LMP-1 functions as a constitutively active tumor ne-
crosis factor receptor, mimicking an activated CD40 re-
ceptor, although structurally different [6,7]. LMP-1 has
pleiotropic functions being able to promote B-cell activa-
tion, homotypic and heterotypic cell adhesion and the ex-
pression of cell surface (i.e. CD23, CD39, CD40 and
CD44) and adhesion (LFA1, ICAM1 and LFA3) molecules.
LMP-1 is also responsible for the up-regulation of anti-
apoptotic proteins, and may suppress cellular senescence.
Particularly relevant from an oncogenic point of view is the
ability of LMP-1 to activate multiple cellular signaling path-
ways, including mitogen-activated protein kinase (MAPK),
c-Jun N-terminal kinase (JNK), phosphatidylinositol 3-
kinase (PI3K)/Akt, and NF-κB [8].
LCLs obtained by EBV infection in vitro of B lympho-
cytes, is considered a useful model to investigate the rela-
tionships between virus and host in the EBV-driven
lymphomagenesis. Indeed, these immortalized cells are
similar to those regularly produced in vivo but negatively
controlled by EBV-specific CD8+ cytotoxic T cells [9].
Studies using this model assess that EBV-driven malignan-
cies and LCLs selectively express latent viral proteins and
maintain their ability to grow indefinitely through in-
appropriate activation of TERT. Expression of latent EBV
proteins is not sufficient to fully immortalize EBV-infected
B cells. Only EBV-carrying B cells with sustained telomer-
ase activity are truly immortalized, whereas telomerase-
negative cells, although exhibiting a prolonged life-span,
eventually undergo cellular senescence and terminate their
life span through the shortening of their telomeres [10,11].
The finding that the majority of EBV-driven tumors
in vivo are telomerase-positive confirms the relevance of
telomerase expression in the process of tumorigenesis.
Pathogenic role of telomerase in cell immortalization and
transformation
Genetic instability is a hallmark of cancer and tumor cells
should circumvent replicative senescence and acquire theability to sustain unlimited proliferation. Telomere/tel-
omerase interplay is an important mechanism involved in
the genomic stability and cellular replicative potential and
its dysfunction has emerged as playing a key role in car-
cinogenesis [12]. Telomeres are specialized DNA struc-
tures located at the end of chromosomes and are essential
in stabilizing chromosomes by protecting them from end-
to-end fusion and DNA degradation. Telomeres are com-
posed of (TTAGGG)n tandem repeats associated with the
telomere-binding proteins TRF1, TRF2, RAP1, TIN2,
TPP1 and POT1, which constitute the shelterin complex
[13]. Telomeres are progressively shortened during each
cell division by replication-dependent loss of sequences at
DNA termini due to the failure of DNA polymerase to
completely replicate the 3′ end of chromosomes [14].
When telomeres become critically short (the Hayflick
limit), cells undergo replicative senescence and apoptosis;
further erosion of telomeres may impair their function in
protecting chromosome ends, resulting in genetic instabil-
ity. Nonetheless, cell division-associated telomere shorten-
ing prevents unlimited cell proliferation and, thus, tumour
development/progression. To escape this proliferation
barrier, cells must stabilize their telomeres. Most tumors
maintain their ability to grow indefinitely through in-
appropriate expression of telomerase, a ribonucleoprotein
complex containing an internal RNA template (TR), used
as a template for elongation of telomeres, and the protein
with telomere-specific reverse transcriptase activity (tel-
omerase reverse transcriptase [TERT]) [15]. While TR has
broad tissue distribution and is constitutively present in
normal and tumour cells, TERT is the rate-limiting com-
ponent of the telomerase complex, and its expression
generally well correlates with telomerase activity. Over-
expression TR along with TERT may increase telomerase
activity, while specific TR variants may reduce its associ-
ation with TERT, thus diminishing the telomerase activity
in telomere lengthening [16]. Expression of TERT is gen-
erally restricted to stem cells, and is usually repressed in
normal somatic cells. It may be expressed at low levels in
normal hematopoietic cells according to their state of dif-
ferentiation/activation. In contrast, TERT is expressed in
the vast majority of immortalized and fully transformed
cells. TERT is essential for unlimited cell growth, and thus
plays a critical role in tumor formation and progression
(reviewed in [17]).
Regulation of telomerase operates at several biological
levels: transcription, mRNA splicing, sub-cellular localiza-
tion of each component, and assembly of TR and TERT in
an active ribonucleoprotein complex. Transcription of
TERT gene is likely the key determinant in the regulation
of telomerase activity; TERT transcriptional activity is spe-
cifically up-regulated in cancer cells, but it is silent in most
normal cells. More than 20 transcription factor-binding
sites acting as activators or repressors have been identified
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is required for full activation of the TERT promoter, while
TP53, through its interaction with SP1, down-regulates
TERT. TERT is also directly activated by nuclear factor
(NF)-kB, hypoxia-inducible factor-1, and the ETS/MYC
complex. The histone methyltransferase SMYD3 also dir-
ectly contributes to inducible and constitutive TERT ex-
pression in normal and malignant human cells. TERT
expression is suppressed by the oncosuppressor genes
WT127 and MEN1, and through the MAD/MYC and the
TGF-β/SMAD pathways. Cell cycle inhibitors p16INK4a
and p27KIP1 have also been shown to down-regulate
TERT expression in cancer cells (reviewed in [17]). Regu-
lation of TERT transcription may also involve DNA
methylation, as the TERT promoter contains a cluster of
CpG sites. At post-transcriptional level, modulation of tel-
omerase may occur by alternative splicings; at least 10 dif-
ferent variants of TERT mRNA have been described, and
some of these splicing products have been proposed to
exert a dominant negative function by competitive inter-
action with components of the telomerase complex [18].
Telomerase activity is also controlled through post-
translational modifications of the TERT protein. Phos-
phorylation of the protein at critical sites by the PI3K/
AKT kinase pathway seems to be crucial for telomerase
activity. Telomere-binding proteins, Telomeric Repeat
binding Factor (TRF)1, TRF2, Repressor/Activator Pro-
tein1 (RAP1), TRF1-interacting Nuclear protein 2 (TIN2),
TTP1 (also known as TINT1, PTOP, PIP1), and Protec-
tion Of Telomers 1 (POT1), which constitute the shelterin
complex, play a role in the activity of telomerase; TPP1
heteromerizes with POT1; the POT1-TPP1 complex is
capable of recruiting and stimulating telomerase activity,
thereby regulating telomere length through TPP1-
telomerase interaction [19]. Notably, recent studies have
suggested that, besides maintenance of telomere length,
TERT is involved in several other cell functions. Expression
of TERT increases replicative kinetics [20,21], promotes
cell growth in adverse conditions and may also act as an
anti-apoptotic agent [22-24]. High levels of telomerase
confer resistance to several antineoplastic drugs [25,26].
Interplay between EBV infection and telomerase
activation in EBV-driven tumors
Although it is well recognized that the establishment of
latent EBV infection and TERT activation are both re-
quired for EBV-driven cell transformation, temporal and
possible causal relationships between these two events
remain to be clarified. Early passages EBV-infected B
lymphocytes greatly differed in their timing of TERT ex-
pression and telomerase activation; EBV-driven B-cell
activation may fail in the induction of telomerase activity
and telomerase-negative EBV-infected B cells may have
a prolonged life-span compared to normal B lymphocytes[10,20]. Although EBV-infected B cells exhibit higher pro-
liferative activity than resting primary B lymphocytes, very
few EBV-carrying B cells will eventually progress to
immortalization, most of them reaching proliferative crisis
and ending their lifespan even after 150 population doub-
ling levels depending on genetic factors, including telo-
mere length. Only LCLs developing a strong telomerase
activity associated with aneuploidy overcome cellular cri-
sis and become stably immortalized. Therefore additional
changes at the cellular level are required to cooperate with
the latent EBV proteins during immortalization of
EBV-infected B cells [10]. It has been recently sug-
gested that telomere length may be maintained in
EBV-infected B lymphocytes by an alternative length-
ening of telomeres (ALT) [27]. However, lack of TERT
activation precluded their long-term establishment in
culture and their immortalization [20].
In primary B lymphocytes, activation of TERT occurs
concomitantly with the induction of latent EBV proteins
and down-regulation of EBV lytic gene expression [20].
We have demonstrated that LMP-1 activates TERT at
the transcriptional level via NF-kB and MAPK/ERK1/2
pathways [28]. LMP-1 induces telomerase activity also in
nasopharyngeal carcinoma cells, an epithelial tumor
closely associated with EBV infection. In these cells,
LMP-1 up-regulates telomerase expression and phoshor-
ylation through the AKT pathway [29]. In epithelial cells,
TERT expression may be also MYC-dependent since
mutagenesis of MYC-responsive E-box elements in the
TERT promoter inhibited TERT transactivation induced
by LMP-1 [30]. In B cells, however, MYC is not involved
in mediating the hTERT expression and telomerase acti-
vation induced by LMP-1, since MYC silencing does not
inhibit LMP-1-induced telomerase activation, and muta-
genesis in the NF-κB binding sites, but not in the MYC
binding sites, inhibits LMP-1-induced activation of the
TERT promoter [28]. This is of particular interest con-
sidering that, while in EBV-negative BL the translocated
and over-expressed MYC plays a key role in TERT acti-
vation, in EBV-positive diffuse large B-cell Lymphomas
and immunoblastic lymphomas where MYC is in germ-
line configuration, TERT is likely to be activated by
LMP-1, as it occurs in LCLs [28].
Notably, in addition to maintaining telomere length
and allowing EBV-infected cells to overcome senescence
and apoptosis, TERT may promote EBV-driven lympho-
magenesis through extra-telomeric functions. One inter-
esting result achieved in vitro using the LCL model is
that TERT expression plays a relevant role in inhibiting
the virus lytic cycle, thereby favouring the induction and
maintenance of EBV latency in primary B lymphocytes,
a prerequisite for EBV-driven transformation. Indeed,
high level of endogenous TERT expression or ectopic
TERT expression on telomerase-negative EBV-infected
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trast, TERT silencing by specific siRNA or short-hairpin
(sh)RNA induced the expression of BZLF1, EA-D, and
gp350 EBV lytic proteins and triggered a complete lytic
cycle. This occurs in both EBV-immortalized LCL and
fully transformed EBV-positive BL cell lines thus sup-
porting the notion that TERT is a critical regulator of
the balance between viral latent and lytic cycles [20,31].
Moreover, TERT inhibition induced an accumulation of
cells in the S phase, an effect likely due to the dephos-
phorylation of 4EBP1, an AKT1-dependent substrate,
which results in a decreased availability of proteins
needed for cell cycle progression. Besides inducing cell
death through activation of complete EBV lytic replica-
tion, TERT inhibition triggered AKT1/FOXO3/NOXA-
dependent apoptosis in EBV-positive and EBV-negative
BL cell lines [31].
The fine mechanism(s) by which TERT prevents the
expression of lytic proteins is still an interesting open
question. It has been demonstrated that the treatment of
primary EBV-positive BL with zidovudine (AZT), a thy-
midine analog, induced EBV lytic cycle and cell death
through the NF-κB pathway [32,33]. Given that AZT
may inhibit telomerase activity [34], this finding further
supports the strong relationship between TERT level
and EBV latent/lytic status and it may suggest that this
occurs via NF-κB pathway. To shed light on the possible
mechanisms underlying the activation of EBV lytic repli-
cation induced by TERT inhibition, a study investigated
the involvement of BATF, a transcription factor, which
negatively regulates AP-1 activity [35,36]. BATF has been
shown to inhibit the expression of BZLF1, thus reducing
EBV lytic replication in latently infected B cells [37]. It
has been shown that ectopic expression of TERT in B
cells significantly increased BATF expression, whereasFigure 1 TERT inhibition induces EBV lytic cycle. In EBV-infected B cells, T
thus preserving EBV latency. Following TERT inhibition, BATF level significantly
proteins and a complete EBV lytic cycle.TERT silencing by shRNA decreased BATF mRNA levels
and protein expression and induced the expression of
lytic protein [31]. These results suggest that TERT silen-
cing promotes the activation of EBV replication by redu-
cing inhibition of BATF-driven BZLF1 transcription
(Figure 1). As viral lytic replication is associated with the
death of infected cells, TERT inhibition may be promis-
ing strategy to treat EBV-driven malignancies.
Telomerase as a promising therapeutic target for human
tumors
The high expression of TERT in tumor cells and the re-
quirement of a sustained telomerase activity for their
unlimited proliferation capability make telomerase a par-
ticularly attractive target for cancer therapy. Moreover,
the fact that rapidly proliferating cancer cells have
shorter telomeres compared to normal somatic cells and
stem cells further corroborates the enhanced specificity
for tumor cells of the cytotoxic effects exerted by drugs
targeting telomerase [38]. Several strategies targeting tel-
omerase are being explored at the pre-clinical level, and
two major approaches are currently under clinical inves-
tigation. Telomerase can be directly targeted by drugs
able to inhibit TERT activity or its RNA template. Alter-
natively, drugs such as G-quadruplex stabilizers, tan-
kyrases or HSP90 inhibitors may act indirectly on
telomerase by preventing its access to telomeres or inhi-
biting binding of telomerase-associated proteins leading
to telomere uncapping and cell apoptosis [39]. GRN163L
(Imetelstat) is a highly promising drug able to inhibit tel-
omerase activity by acting as a direct telomerase RNA
template antagonist rather than behaving as a normal
antisense oligonucleotide [40]. This compound has been
successfully tested in several phase I studies involving
patients with non-small cell lung cancer, locally recurrentERT up-regulates the expression of BATF, a negative regulator of BZLF1,
decreases; the expression of BZLF1 leads to the induction of lytic
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thrombocythemia and its efficacy is now being investi-
gated in phase II clinical trials [39]. Among small mol-
ecule inhibitors targeting hTERT, the non-nucleosidic
compound BIBR1532 is particularly interesting due to its
ability to inhibit telomerase by non-competitively binding
to the active site of TERT [41]. Preclinical studies carried
out with cell lines of different tumor histotypes demon-
strated that BIBR1532 can inhibit telomerase activity and
induce cell growth arrest without causing acute cytotox-
icity. Evidence has been also provided indicating that
BIBR1532 can sensitize tumor cells to chemotherapy
[42,43]. T-oligo is a newly developed drug composed of a
single stranded 11-bp oligonucleotide with sequence hom-
ology to telomeres able to potently induce DNA damage
responses including apoptosis, differentiation and senes-
cence [44,45]. Notably, in normal cells, T-oligo induces
only transient antiproliferative effects due to the presence
of functional cell cycle check points [45]. Given that telo-
mere length depends on the balance between progressive
loss during cell proliferation and extension induced by
telomerase activation, a deeper knowledge of telomere/
telomerase interplay is critical to choose the most appro-
priate timing for administering telomerase-targeted
drugs. This is a highly relevant issue to design the most
effective schedules of treatment including these innova-
tive drugs.
A second main therapeutic approach involves im-
munotherapy strategies targeting telomerase [39]. Con-
sidering that most cancers express telomerase, peptides
derived by this protein can be considered as universal
tumor-associated antigens. Indeed, evidence accumu-
lated so far clearly indicates that telomerase-derived
peptides may elicit specific CD8+ and CD4+ T cell re-
sponses of potential clinical relevance [46,47]. Several
strategies are being investigated to enhance the im-
munogenicity of TERT-based vaccines, including the use
of adjuvants like GM-CSF or TLR-7 (GV1001 vaccine)
[48] or the generation of cryptic peptide vaccines, such
as Vx-001 [49]. In these latter vaccines, one amino acid
residue of a TERT peptide is replaced for another result-
ing in a higher affinity to the presenting HLA molecule
and a more efficient stimulation of TERT-specific T cells
[49]. In addition to these peptide-based vaccines, im-
munotherapy approaches targeting TERT also include
dendritic cell-based vaccines, which do not suffer from
the limitations imposed by HLA restriction. GRNVAC1
is a vaccine composed of immature dendritic cells trans-
fected ex vivo with a chimeric mRNA encoding the en-
tire TERT sequence and a portion of the lysosomal-
associated membrane protein, which redirects the TERT
protein to the lysosome degradation pathway favoring its
degradation into immunogenic peptides [50]. Several
TERT-targeting vaccines have successfully completedphase I/II studies and are now being investigated in
phase III clinical trials.
Strategies exploiting telomerase/TERT inhibition for the
treatment of EBV-driven tumors
The observation that EBV-driven tumors generally ex-
press telomerase at high levels provides the rationale
supporting the use of the aforementioned pharmaco-
logical and immunological approaches targeting telomer-
ase/TERT also for the treatment of these malignancies.
Nevertheless, exploitation of telomerase inhibition in
this setting may offer additional advantages of potential
clinical relevance. In fact, our observation that inhibition
of TERT by shRNA triggers virus replication in both
EBV-immortalized and fully transformed B cells [31]
provides the highly promising opportunity to combine
TERT inhibition with antiviral drugs to improve the rate
of clinical responses. Indeed, there is an increasing inter-
est in developing strategies able to reactivate EBV lytic
gene expression in latently infected tumor cells for the
treatment of overt EBV-associated lymphomas. In fact,
lytic infection may promote the death of EBV-positive
lymphoma cells in vivo, an effect that may be therapeut-
ically relevant since it also favours immune recognition
of viral antigens that further enhances the killing of
tumor cells. Therefore, drugs targeting cells undergoing
viral replication may be used not only to prevent or con-
tain the spreading of EBV infection, but also mainly for
their cytotoxic activity on the infected cells and the adja-
cent cells [51]. Several chemotherapeutic drugs are
known to trigger EBV replication, and combination of
antivirals with lytic cycle inducers is emerging as a
promising strategy for the treatment of EBV-driven
lymphomas [52]. We have recently demonstrated that
ganciclovir markedly enhances the the anti-proliferative
and pro-apoptotic effects induced by TERT inhibition in
both EBV-positive BL cells and LCLs [31]. This is prob-
ably related to induction of EBV replication and may be
the result of the activation of the pro-drug by EBV lytic
products such as the viral thymidine kinase or viral pro-
tein kinase. In this respect, drugs able to inhibit TERT
may be regarded as sensitizers for the activity of antivi-
rals. On these grounds, the combination of antiviral
drugs with strategies able to inhibit TERT expression/ac-
tivity may result in therapeutically relevant effects in pa-
tients with EBV-related malignancies. This possibility
appears particularly promising in light of the recent de-
velopment of potent and specific telomerase inhibitors.
In EBV-associated tumors, telomerase can be also tar-
geted indirectly by strategies that inhibit the expression
of LMP-1, the major viral oncoprotein endowed with
pleiotropic effects also including the ability to up-
regulate TERT at the transcriptional level [28,29]. In this
respect, it has been demonstrated that inhibition of
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LMP-1 mRNA down-regulates the expression of the
catalytic subunit of telomerase (TERT), both at the pro-
tein and mRNA levels, and consequently inhibits telomer-
ase activity in LMP1-positive nasopharyngeal carcinoma
cells [29]. Similar strategies may be adopted with thera-
peutic purposes also for EBV-driven lymphomas.
Conclusions
Available evidence indicates that TERT expression and
telomerase activation play a critical role in EBV-driven
tumorigenesis. Several therapeutic strategies for telomer-
ase inhibition have been developed and are being investi-
gated in clinical trials, although data concerning the
response rates obtained in patients with EBV-associated
lymphomas are limited. Most therapeutics have shown
to be more effective when used in combination with
standard therapies. In this respect, our finding that TERT
inhibition sensitizes EBV+ lymphoma cells to antivirals
through activation of EBV lytic replication is particularly
promising and provides a rationale for conducting further
research to assess the effects of combination therapies
with TERT inhibitors and antivirals for the treatment of
EBV-associated malignancies.
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